NASDAQ:CALA - Calithera Biosciences, Inc.
$5.31
 $0.09
+1.72%
1:30PM EDT
2019-02-15
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CALA     avg for
industry  
  avg for
sector  
42 stocks weight:  16. 87   0. 00   0. 00  
42 stocks rank:  3. 75 K 1. 86 K 1. 09 K
# analyst opinions:  4. 00   14. 92   14. 43  

quick ratio:  13. 51   5. 37   1. 81  
current ratio:  13. 66   5. 69   2. 19  

target price low:  6. 37   88. 97   117. 82  
target price avg:  7. 00   115. 19   141. 96  
target price high:  12. 25   143. 40   163. 16  
1-yr high:  9. 05   124. 30   142. 77  
last close:  5. 22   101. 85   127. 84  
50-day avg:  4. 46   98. 27   122. 46  
200-day avg:  4. 93   99. 72   122. 70  
1-yr low:  3. 62   78. 19   100. 16  
volume:  92. 29 K 2. 38 M 4. 64 M
50-day avg volume:  189. 17 K 3. 31 M 4. 94 M
200-day avg volume:  322. 28 K 3. 23 M 4. 28 M

1-day return:  -1. 32 % 0. 22 % 0. 48 %
this week return:  7. 41 % 1. 77 % 2. 01 %
12-wk return:  6. 31 % 6. 56 % 3. 33 %
52-wk return:  -26. 20 % -2. 23 % 14. 35 %

enterprise value (EV):  58. 32 M 55. 17 B 104. 51 B
market cap:  199. 02 M 49. 01 B 96. 46 B
EBITDA:  -48. 11 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -1. 21   -91. 79   2. 29  
enterprise/revenue (EV/R):  1. 98   29. 84   23. 39  
total revenue:  29. 51 M 11. 28 B 40. 22 B
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -46. 10 M 2. 37 B 3. 58 B

shares outstanding:  38. 13 M 607. 99 M 1. 22 B
shares:  32. 93 M 605. 53 M 1. 15 B
shares short:  648. 77 K 11. 62 M 12. 55 M
shares short prior month:  604. 96 K 11. 95 M 13. 44 M
short ratio:  4. 00   4. 82   3. 10  
short % of float:  2. 47 % 6. 19 % 2. 82 %
total cash/share:  3. 71   12. 02   11. 46  
total cash:  141. 46 M 7. 41 B 7. 37 B
free cash flow:  -47. 17 M 95. 99 M 2. 04 B
operating cash flow:  -62. 32 M 164. 74 M 3. 04 B

book value:  3. 65   14. 43   28. 26  
price/book:  1. 43   -1. 57   -2. 97  
gross profits:  -17. 16 M 8. 28 B 18. 09 B
operating margins:  -164. 70 % -458. 01 % -642. 83 %
EBITDA margins:  -163. 05 % 13. 81 % 22. 47 %
profit margins:  -156. 24 % 6. 57 % 9. 92 %
gross margins:  -119. 31 % 49. 33 % 54. 53 %

1-yr max volatility:  16. 55 % --- ---
1-yr mean volatility:  -0. 04 % 0. 01 % 0. 06 %

1-yr EPS:  -1. 28   3. 03   4. 09  
forward EPS:  -2. 08   4. 33   6. 99  
P/E:  -4. 07   6. 11   26. 91  
forward P/E:  -2. 54   8. 38   10. 48  
PE/G:  0. 23   0. 37   5. 61  
growth:  -17. 52 % 683. 72 % 104. 79 %
earnings high:  -0. 34   1. 27   1. 66  
earnings avg:  -0. 49   1. 01   1. 53  
earnings low:  -0. 58   0. 76   1. 40  
revenue high:  6. 90 M 2. 86 B 11. 19 B
revenue avg:  1. 73 M 2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -17. 20 % -3. 27 % 3. 81 %
return on equity:  -31. 36 % 107. 48 % 27. 82 %
revenue/share:  0. 82   14. 68   59. 83  

beta (1yr vs S&P500):  0. 88   1. 21   0. 93  
sharpe (1yr):  -0. 16   0. 06   0. 98  

held % insiders:  1. 35 % 6. 46 % 3. 21 %
held % institutions:  63. 59 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : CALA
.    + 1.001 =         1.001 :: INITIAL WEIGHT
.  + 337.268 =       338.269 :: inverse volume-to-price addition
.  + 298.675 =       636.944 :: spline projection addition
.  - 143.791 =       493.153 :: poor performance penalty
.    x 0.838 =       413.241 :: one-year gains+dividend factor
.     x 9.37 =      3872.044 :: 13 weeks' performance factor
.    x 1.492 =      5778.983 :: industry recommendation factor
.    x 1.066 =      6161.912 :: EV/R factor
.    x 0.998 =      6151.314 :: return on assets factor
.    x 0.997 =      6132.021 :: return on equity factor
.    x 2.398 =     14707.635 :: current ratio factor
.    x 1.039 =     15284.216 :: quick ratio factor
.    x 1.118 =     17088.273 :: short ratio factor
.    x 2.014 =      34420.73 :: price-to-book factor
.    x 1.045 =     35980.563 :: 5-day avg > 200-day avg
.    x 1.154 =     41524.094 :: 5-day avg > 50-day avg
.    x 2.151 =     89307.448 :: P/E weight
.    x 1.441 =    128677.503 :: PE/G factor
.    x 1.653 =    212661.319 :: beta factor
.    x 0.158 =     33538.535 :: sharpe factor
.    x 1.485 =     49806.189 :: target low factor
.    x 1.195 =     59500.943 :: target mean factor
.    x 1.116 =     66405.984 :: target high factor
.    x 1.066 =     70763.067 :: industry 12-weeks return
.    x 0.981 =     69395.472 :: "drift" penalty 1 days ago
.    x 0.973 =     67518.385 :: "drift" penalty 2 days ago
.    x 0.996 =     67225.485 :: overall "drift" factor
.    x 0.854 =      57406.03 :: largest single-day jump factor
.    x 0.084 =      4799.835 :: low price factor
.      x 1.0 =      4800.157 :: factor hist industry gain for week 06
.   cubeRoot =        16.869 :: reduced for readability
.                     16.869 :: FINAL WEIGHT for NASDAQ:CALA


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org